The Safety and Efficacy of GLP-1 Receptor Agonists in Heart Failure Patients: A Systematic Review and Meta-Analysis
Authors:
- 20 January 2023
- journal article
- review article
- Published by Elsevier in Current Problems in Cardiology
- Vol. 48 (5) , 101602
Abstract
No abstract availableKeywords
This publication has 23 references indexed in Scilit:
- Effects of Once-Weekly Exenatide on Cardiovascular Outcomes in Type 2 DiabetesNew England Journal of Medicine, 2017
- Liraglutide and Renal Outcomes in Type 2 DiabetesNew England Journal of Medicine, 2017
- Effects of liraglutide on hemodynamic parameters in patients with heart failureOncotarget, 2017
- Effects of the Novel Long-Acting GLP-1 Agonist, Albiglutide, on Cardiac Function, Cardiac Metabolism, and Exercise Capacity in Patients With Chronic Heart Failure and Reduced Ejection FractionJACC: Heart Failure, 2016
- Effects of liraglutide on left ventricular function in patients with non-ST-segment elevation myocardial infarctionEndocrine, 2015
- Angiotensin–Neprilysin Inhibition versus Enalapril in Heart FailureNew England Journal of Medicine, 2014
- Cardiovascular and metabolic effects of 48-h glucagon-like peptide-1 infusion in compensated chronic patients with heart failureAmerican Journal of Physiology-Heart and Circulatory Physiology, 2010
- Cardioprotective and Vasodilatory Actions of Glucagon-Like Peptide 1 Receptor Are Mediated Through Both Glucagon-Like Peptide 1 Receptor–Dependent and –Independent PathwaysCirculation, 2008
- Glucagon-Like Peptide-1 Infusion Improves Left Ventricular Ejection Fraction and Functional Status in Patients With Chronic Heart FailureJournal of Cardiac Failure, 2006
- Effects of Glucagon-Like Peptide-1 in Patients With Acute Myocardial Infarction and Left Ventricular Dysfunction After Successful ReperfusionCirculation, 2004